Research progress of general anesthesia in the pharmacogenetics

doi:10.12092/j.issn.1009-2501.2018.02.019

Abstract

Abstract:

General anesthesia is a state of unconsciousness, amnesia, analgesia and akinesia induced by drugs used in general anesthesia. Along with the development of pharmacogenetics and pharmacogenomics, pharmacogenetic studies of these drugs have been carried out continuously. This review summarizes the pharmacogenetics of commonly used general anesthesia drugs like analgesics, sedative-hypnotics, neuromuscular blockers and antiemetics in recent years.

Key words: general anesthesia, pharmacogenetics, pharmacogenomics

CLC Number:

R968

XIE Shangchen, LI Wei, LIAO Ping, HE Yijing, MCLEOD Howard L.. Research progress of general anesthesia in the pharmacogenetics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 217-222.

References

［1］Brown EN, Lydic R, Schiff ND.General anesthesia, sleep, and coma［J］. N Engl J Med, 2010, 363(27): 2638-2650.
［2］Sadhasivam S, Chidambaran V, Zhang X, et al. Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics ［J］. Pharmacogenomics J, 2015, 15(2): 119-126.
［3］Bastami S, Gupta A, Zackrisson AL, et al. Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption ［J］. Basic Clin Pharmacol Toxicol, 2014, 115(5): 423-431.
［4］Matic M, Simons SH, van Lingen RA, et al. Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype ［J］. Pharmacogenomics, 2014, 15(10): 1287-1295.
［5］Venkatasubramanian R, Fukuda T, Niu J, et al. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children ［J］. Pharmacogenomics, 2014, 15(10): 1297-1309.
［6］付孟龙, 周宏灏. MDR1基因多态性及其临床相关性［J］. 中国临床药理学与治疗学, 2016, 21(4): 463-469.
［7］Lee MG, Kim HJ, Lee KH,et al. The influence of genotype polymorphism on morphine analgesic effect for postoperative pain in children ［J］. Korean J Pain, 2016, 29(1): 34-39.
［8］Sia AT, Lim Y, Lim EC, et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia ［J］. Anesthesiology, 2008, 109(3): 520-526.
［9］Nielsen LM, Sverrisdóttir E, Stage TB, et al. Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics ［J］. Eur J Pharm Sci, 2017, 99:337-342.
［10］Tzvetkov MV, dos Santos Pereira JN, Meineke I, et al. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration ［J］. Biochem Pharmacol, 2013, 86(5): 666-678.
［11］Dean L. Codeine therapy and CYP2D6 genotype［M］ //Pratt V, Mcleod H, Dean L, et al. Medical genetics summaries. Bethesda (MD). 2012.
［12］Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism ［J］. N Engl J Med, 2004, 351(27): 2827-2831.
［13］Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death ［J］. N Engl J Med, 2009, 361(8): 827-828.
［14］Friedrichsdorf SJ, Nugent AP, Strobl AQ. Codeine-associated pediatric deaths despite using recommended dosing guidelines: three case reports ［J］. J Opioid Manag, 2013, 9(2): 151-155.
［15］Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update［J］. Clin Pharmacol Ther, 2014, 95(4): 376-382.
［16］Baber M, Chaudhry S, Kelly L, et al. The pharmacogenetics of codeine pain relief in the postpartum period ［J］. Pharmacogenomics J, 2015, 15(5): 430-435.
［17］Bell GC, Donovan KA, Mcleod HL. Clinical implications of opioid pharmacogenomics in patients with cancer ［J］. Cancer Control, 2015, 22(4): 426-432.
［18］Tanaka N, Naito T, Yagi T, et al. Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period［J］.Ther Drug Monit, 2014, 36(3): 345-352.
［19］Ishida T, Naito T, Sato H, et al. Relationship between the plasma fentanyl and serum 4beta-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain ［J］. Drug Metab Pharmacokinet, 2016, 31(3): 242-248.
［20］Koolen SL, Van der Rijt CC. Is there a role for pharmacogenetics in the dosing of fentanyl ［J］ ? Pharmacogenomics, 2017, 18(5): 417-419.
［21］Mieda T, Nishizawa D, Nakagawa H, et al. Genome-wide association study identifies candidate loci associated with postoperative fentanyl requirements after laparoscopic-assisted colectomy ［J］. Pharmacogenomics, 2016, 17(2): 133-145.
［22］Hohmann N, Kocheise F, Carls A, et al. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans ［J］. Br J Clin Pharmacol, 2015, 79(2): 278-285.
［23］Seng KY, Hee KH, Soon GH, et al. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients ［J］. J Clin Pharmacol, 2014, 54(2): 215-224.
［24］De Jonge H, Elens L, de loor H, et al. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients ［J］. Pharmacogenomics J, 2015, 15(2): 144-152.
［25］Elens L, Nieuweboer AJ, Clarke SJ, et al. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin ［J］. Pharmacogenet Genomics, 2013, 23(3): 148-155.
［26］Mikstacki A, Skrzypczak-Zielinska M, et al. The impact of genetic factors on response to anaesthetics ［J］. Adv Med Sci, 2013, 58(1): 9-14.
［27］Mourao AL, DE abreu FG, Fiegenbaum M. Impact of the cytochrome P450 2B6 (CYP2B6) gene polymorphism c.516G>T (rs3745274) on propofol dose variability ［J］. Eur J Drug Metab Pharmacokinet, 2016, 41(5): 511-515.
［28］Eugene AR.CYP2B6 genotype guided dosing of propofol anesthesia in the elderly based on nonparametric population pharmacokinetic modeling and simulations［J］. Int J Clin Pharmacol Toxicol, 2017, 6(1): 242-249.
［29］Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia ［J］. Science, 1991, 253(5018): 448-451.
［30］Rosenberg H, Pollock N, Schiemann A, et al. Malignant hyperthermia: a review ［J］. Orphanet J Rare Dis, 2015, 10: 93.
［31］Alvarellos ML, McDonagh EM, Patel S, et al.PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics ［J］. Pharmacogenet Genomics, 2015, 25(12): 622-630.
［32］Garcia DF, Oliveira TG, Molfetta GA, et al. Biochemical and genetic analysis of butyrylcholinesterase (BChE) in a family, due to prolonged neuromuscular blockade after the use of succinylcholine ［J］. Genet Mol Biol, 2011, 34(1): 40-44.
［33］Gatke MR, Bundgaard JR, Viby-mogensen J. Two novel mutations in the BCHE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia ［J］. Pharmacogenet Genomics, 2007, 17(11): 995-999.
［34］Wichmann S, Faerk G, Bundgaard JR, et al. Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene ［J］. Pharmacogenet Genomics, 2016, 26(7): 351-356.
［35］Costa CC, Coelho EB, Lanchote VL, et al. The SLCO1A2 -189-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries ［J］. Eur J Clinl Pharmacol, 2017, 73(8): 957-963.
［36］Mei Y, Wang SY, Li Y, et al. Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients ［J］. J Clin Pharmacol, 2015, 55(3): 261-268.
［37］Bell GC, Caudle KE, Whirl-carrillo M, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron ［J］. Clin Pharmacol Ther, 2017, 102(2): 213-218.
［38］He H, Yin JY, Xu YJ, et al. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting ［J］. Clin Ther, 2014, 36(8): 1242-1252 e2.
［39］Farhat K, Iqbal J, Waheed A, et al.Association of anti-emetic efficacy of ondansetron with G2677T polymorphism in a drug transporter gene ABCB1 in pakistani population ［J］. J Coll Physicians Surg Pak, 2015, 25(7): 486-490.
［40］Farhat K, Waheed A, Hussain A, et al. Influence of genetic variations in ABCB1 on the clinical efficacy of ondansetron- A pharmacogenetic analysis of Pakistani population ［J］［J］. J Pak Med Assoc, 2015, 65(9): 963-966.
［41］郭成贤, 王晶, 李金高, 等.临床药物基因组学应用现状［J］.中国临床药理学与治疗学, 2016, 21(4): 458-462.

[1]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[2]	SUN Yuanyuan, DENG Kunhong, WANG Siyi, KUANG Yun, ZOU Chan, GUO Chengxian, HE Qingnan, LIU Helin, YANG Guoping. Design and implementation of electronic identity application for gene-directed personalized medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 274-280.
[3]	YANG Jie, CAO Junli, LIU He. Research progress on the effect of noninvasive neuromodulation technique on patients with postoperative sleep disturbances after general anesthesia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1322-1332.
[4]	NI Yuanbo, ZHANG Xin, LI Yi, LIU Cunming. Anesthetics, analgesics and cognitive function [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1365-1374.
[5]	DING Jiahui, ZHOU Yu, YUAN Tianjie, XIA Junming, LI Wenxian, HAN Yuan. Research progress of anesthesia-related neural network in depth of anesthesia monitoring [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1400-1407.
[6]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
[7]	JIN Baowei, JIANG Zongming, GUO Jianrong. Clinical application and research progress of remimazolam [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1444-1448.
[8]	. Research Progress of Pharmacogenomics of Dabigatran Etexilate and Rivaroxaban [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1200-1207.
[9]	YING Haifeng, ZHANG Weiping, YOU Kuangzhang, CHEN Lingyang. Analgesia effect of small amount of buprenorphine on children undergoing laparoscopic hernia repair under general anesthesia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 916-921.
[10]	XU Wei, QU Weimin, HONG Zongyuan. Advances in research on the mechanism of general anesthesia by specific manipulation of neuron activities [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 825-829.
[11]	ZHAO De-heng, XIAO Hui-lai. FDA's recommentdations on pharmacogenomics studies in early-phase clinical studies [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 208-212.
[12]	ZHANG Yue-li, MING Ying-zi, ZHOU Hong-hao, ZHANG Wei. Tacrolimus pathways:pharmacokinetics,pharmacodynamics and pharmacogenomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1042-1049.
[13]	ZHENG Yi, YIN Ji-ye, ZHOU Hong-hao, LIU Zhao-qian. Advances in relationship of genetic polymorphism with the toxicity caused by platinum-based therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1051-1056.
[14]	WU Si-lian, CHENG Yong-quan, JIN Xiao-ju. Effects of compound lidocaine cream in the endotracheal tube extubation of pediatric abdominal surgery under general anesthesia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 801-804.
[15]	LI Mu-peng, XIONG Yan, CHEN Xiao-ping. Progress in pharmacokinetics, pharmacodynamics and pharmacogenetics of the antiplatelet drug ticagrelor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 214-222.